This study is a multicenter, prospective, observational real-world study designed to investigate and analyze the current treatment patterns of chronic hepatitis B (CHB) across 200 hospitals in China. By comparing patient outcomes under different therapeutic regimens, it aims to provide high-quality evidence-based medical data to optimize CHB treatment strategies and follow-up protocols, ultimately contributing to the advancement of a functional cure for chronic hepatitis B.
1.Chronic HBV infection (HBsAg-positive for ≥6 months); 2.Age ≥18 years; 3.Patients who, based on real-world clinical practice needs, are planned or currently receiving treatment with:Entecavir (ETV),Tenofovir disoproxil fumarate (TDF),Tenofovir alafenamide fumarate (TAF),Tenofovir amibufenamide (TMF) OR Pegylated interferon α-2b-naïve patients OR Patients re-initiating pegylated interferon α-2b therapy; 4.Written informed consent obtained from the patient.
1.Severe hepatic dysfunction or decompensated cirrhosis; 2.Concurrent participation in other clinical trials; 3.Hepatocellular carcinoma (HCC).
Patients were selected from chronic hepatitis B (CHB) cases across 200 national hospitals
Cohort
Prospective
ETV,TDF,TAF,TMF
Drugtreated with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF)
Peginterferon α-2b injection
Drugtreated with Peginterferon α-2b injection
Percentage of patients with HBsAg-associated HCC post-therapy
Hepatocellular Carcinoma (HCC) Incidence
Number of chronic hepatitis B (CHB) patients with accurate knowledge/awareness of HBV
Rate of HBsAg seroclearance
HBsAg seroconversion rate
Number of patients with altered HBsAg levels post-treatment
Click on the lead sponsor to view all of their trials.
